ACRS Q4 2025 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q4 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$1M-85.9% YoY

Gross Profit

$2M162.0% margin

Operating Income

-$23M-1755.5% margin

Net Income

-$20M-1528.6% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-60.7%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$160M

Total Liabilities

$57M

Stockholders' Equity

$103M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$9M	-85.9%
Gross Profit	$2M	-$90,000	+2431.1%
Operating Income	-$23M	-$100M	+77.2%
Net Income	-$20M	-$97M	+79.5%

Revenue Segments

License and Service

$795,00061%

Contract research

$500,00039%